Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Inv. presentation
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Appointed director

IMPAX LABORATORIES INC (IPXL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2011 BW Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson's Disease
07/06/2011 BW Robbins Umeda LLP Announces an Investigation of Impax Laboratories, Inc.
06/30/2011 BW Impax Laboratories Announces Settlement of Litigation Relating to WELCHOL® Tablets and WELCHOL® Oral Suspension Products
06/06/2011 BW Impax Laboratories Provides an Update on Recent FDA Site Inspection
06/01/2011 BW Data on IPX066 ADVANCE-PD and APEX-PD Phase III Studies to be Presented at the International Congress of Parkinson's Disease and Movement Disorders Conference
05/10/2011 BW Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159
05/06/2011 BW Impax Laboratories Confirms Patent Suit Relating to Generic Concerta® 18, 27 and 36 mg Tablets
05/06/2011 BW Impax Laboratories to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
05/03/2011 BW Impax Laboratories Reports First Quarter 2011 Financial Results
05/02/2011 BW Impax Laboratories Appoints Mark A. Schlossberg as Senior Vice President and General Counsel
04/14/2011 BW Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2011 Financial Results
04/11/2011 BW Impax Laboratories Confirms Patent Challenge Relating to OXYCONTIN® 10, 15, 20, 30, 40, 60, and 80 mg
04/08/2011 BW Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps
04/04/2011 BW Impax Laboratories Confirms Patent Challenge Relating to DEXILANT® Delayed-Release Capsules, 30 mg and 60 mg
04/01/2011 BW Data on IPX066 APEX-PD Phase III Study for the Treatment of Early Parkinson's Disease to be Presented at the American Academy of Neurology Conference
03/14/2011 BW IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of Advanced Parkinson's Disease
03/01/2011 BW Impax Laboratories to Present at the Cowen & Co. 31st Annual Health Care Conference
02/25/2011 BW Impax Laboratories to Present at the RBC Capital Markets' Healthcare Conference
02/24/2011 BW Impax Laboratories Reports Fourth Quarter and Record Full Year 2010 Financial Results
02/18/2011 BW Impax Laboratories Receives Final FDA Approval for Generic Adoxa® 150 mg Capsules
12/03/2010 BW Impax Laboratories Confirms Patent Challenge Relating to INTUNIVTM, 4 mg
11/29/2010 BW Impax Laboratories Confirms Patent Suit Relating to Generic Concerta® 54 mg Tablets
11/26/2010 BW Impax Laboratories to Present at the Piper Jaffray Annual Healthcare Conference
11/26/2010 BW Impax Laboratories Confirms Patent Challenge Relating to SIMCOR® Extended-Release Tablets, 1000/20 mg
11/22/2010 BW Impax Confirms Patent Challenge Relating to WELCHOL® for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet
11/16/2010 BW Impax Laboratories Receives Final FDA Approval for Generic Allegra-D 60mg/120mg Tablets
11/05/2010 BW Impax Laboratories to Present at the Credit Suisse 19th Annual Healthcare Conference
11/01/2010 BW Impax Laboratories Announces Litigation Against Shire Relating to Supply of Generic Adderall XR®
10/04/2010 BW Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2010 Financial Results
09/30/2010 BW Impax Laboratories to Present at the Jefferies 2010 Global SpecPharma and European Healthcare Conference
09/15/2010 BW Impax Laboratories to Present at the UBS Global Life Sciences Conference
09/08/2010 BW Impax Laboratories to Present at the Morgan Stanley Global Healthcare Conference
08/03/2010 BW Impax Laboratories Continues Strong Growth in Revenue, Profit and Earnings in the Second Quarter 2010
07/22/2010 BW Impax Laboratories Receives Final FDA Approval for Generic OPANA® ER Tablets
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy